OSU 6162

Drug Profile

OSU 6162

Alternative Names: Movement disorder therapeutics - Pfizer; PNU-9639; PNU-96391; PNU-96391A

Latest Information Update: 22 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Carlsson Research AB
  • Developer Carlsson Research AB; NeuroSearch; Pfizer
  • Class Antipsychotics; Piperidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor modulators; Dopamine D2 receptor partial agonists; Serotonin 2 receptor modulators; Serotonin 2A receptor partial agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic fatigue syndrome; Stroke
  • Discontinued Parkinson's disease

Most Recent Events

  • 11 Jul 2017 Oslo University Hospital plans a phase II trial for Fatigue (secondary to aneurysmal subarachnoid haemorrhage) in Norway (NCT03209830)
  • 20 Mar 2017 Phase-II clinical trials in Stroke in Sweden (PO) (EudraCT2016-003888-19)
  • 04 Feb 2016 OSU 6162 is still in phase II trials for Chronic fatigue syndrome in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top